The second article in this series, Standards for Clinical Trials in Male and Female Sexual Dysfunction, focuses on measurement of patient-reported outcomes (PROs). Together with the design of appropriate phase I to phase IV clinical trials, the development, validation, choice, and implementation of valid PRO measurements-the focus of the present article-form the foundation of research on treatments for male and female sexual dysfunctions. PRO measurements are assessments of any aspect of a patient's health status that come directly from the patient (ie, without the interpretation of the patient's responses by a physician or anyone else). PROs are essential for assessing male and female sexual dysfunction and treatment response, including symptom frequency and severity, personal distress, satisfaction, and other measurements of sexual and general health-related quality of life. Although there are some relatively objective measurements of sexual dysfunction (ie, intravaginal ejaculatory latency time, frequency of sexual activity, etc), these measurements do not comprehensively assess the occurrence and extent of sexual dysfunction or treatment on the patient's symptoms, functioning, and well-being. Data generated by a PRO instrument can provide evidence of a treatment benefit from the patient's perspective.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jsxm.2016.08.015 | DOI Listing |
ERJ Open Res
January 2025
Department of Otolaryngology-Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA, USA.
Background: Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are prevalent disease complications in people with cystic fibrosis. These understudied comorbidities significantly impact quality of life. The impact of highly effective modulator therapy (HEMT) in young children with cystic fibrosis (YCwCF) on these disease complications is unknown.
View Article and Find Full Text PDFMedicine (Baltimore)
November 2024
College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Utilizing network pharmacology and molecular docking, we evaluated the possible pharmacological mechanism of Danggui Sini Decoction (DGSND) for treating erectile dysfunction (ED). DGSND's chemical components and targets were found utilizing the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Disease-related genes associated with ED were identified through GeneCards, OMIM, TTD, DrugBank, and DisGeNET databases.
View Article and Find Full Text PDFSex Med
December 2024
Department of Psychiatry, Faculty of Medicine and Health Sciences, Universiti Putra, Malaysia.
Background: In Asian countries, discussing sex-related issues remains a taboo. Sexual dysfunction is not even considered a serious disorder in Pakistan.
Aim: To explore sexual dysfunction and marital satisfaction within the Pakistani context to develop supportive intervention programs.
J Med Case Rep
January 2025
Department of Urology, SRM Institute of Science and Technology, SRM Nagar, Chengalpattu, Kattankulathur, Tamilnadu, 603203, India.
Background: The diagnosis and management of female genital conditions (Rodriguez et al. in Clin Anat 34(1):103-107, 2020. https://doi.
View Article and Find Full Text PDFJ Sex Med
January 2025
Department of Gynecology and Obstetrics, Health Sciences University Ankara Training and Research Hospital, Ankara Altındağ 06230, Türkiye.
Background: Sexual dysfunction (SD) is a complication of poorly managed diabetes mellitus (DM). To prevent SD, patients should develop sexual health literacy (SHL).
Objective: This study investigated the relationship between SHL and SD in women with DM.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!